Last updated: February 13, 2026
What is ND: 70710-1460?
ND: 70710-1460 refers to Eptinezumab, marketed under the brand name Vyepti. It is a monoclonal antibody developed by Lundbeck and Alder BioPharmaceuticals (now part of Lundbeck following their acquisition of Alder). Approved by the U.S. Food and Drug Administration (FDA) in February 2020, Eptinezumab targets CGRP (calcitonin gene-related peptide) for preventive treatment of migraine in adults.
Market Size and Current Adoption
Global Migraine Market
The global migraine market was valued at approximately $3.3 billion in 2022. It is expected to grow at a compound annual growth rate (CAGR) of 4-6% through 2030, driven by increasing migraine prevalence, novel therapeutic options, and expanding insurance coverage.
Target Population
Approximately 39 million Americans suffer from migraines, with around 16% of women and 6% of men affected.[1] The adult population in the U.S. eligible for preventive migraine therapies exceeds 25 million.
Market Share of CGRP Inhibitors
Eptinezumab, alongside erenumab (Aimovig), fremanezumab (Ajovy), and galcanezumab (Emgality), accounts for roughly 70% of the preventives market in the U.S. among CGRP agents.[2]
Competitive Landscape
| Drug |
Company |
Approval Date |
Frequency |
Price per Dose |
Annual Cost |
Market Position |
| Eptinezumab (Vyepti) |
Lundbeck |
Feb 2020 |
IV, Q 3 months |
$3,200 |
$12,800 |
Recently launched, high efficacy for acute SI relief |
| Erenumab (Aimovig) |
Amgen/Novartis |
May 2018 |
SC, Q 1 month |
$6,900 |
$82,800 |
First to market, most widely adopted |
| Fremanezumab (Ajovy) |
Teva |
Sept 2018 |
SC, Q monthly or quarterly |
$6,900 |
$27,600 |
Flexible dosing, second most adopted |
| Galcanezumab (Emgality) |
Eli Lilly |
Sept 2018 |
SC, Q monthly |
$6,900 |
$82,800 |
Strong marketing focus, high reimbursement |
Eptinezumab's intravenous route offers rapid onset of effect, which appeals to specific patient subsets.
Pricing Trends and Projections
Historical Pricing Analysis
- Launch Price: ~$3,200 per dose in 2020.
- Price Adjustment: Slight reductions in volume-based discounts and negotiated reimbursement rates observed since launch.
- Market Uptake: Initially limited due to IV administration requirement, now gaining ground with increased clinical familiarity.
Projected Price Trends (2023-2028)
| Year |
Estimated Price per Dose |
Comments |
| 2023 |
$3,000 - $3,200 |
Stabilization, based on reimbursement negotiations |
| 2024 |
$2,800 - $3,200 |
Slight decline due to increased competition |
| 2025 |
$2,700 - $3,000 |
Price competition intensifies, value-based pricing models gain prominence |
| 2026 |
$2,500 - $2,800 |
Potential for bundle discounts, volume-based agreements |
| 2027-2028 |
$2,300 - $2,700 |
Continued downward pricing trend, driven by market saturation |
Factors Influencing Pricing
- Route of Administration: IV infusion incurs higher administration costs versus SC injections, impacting payer reimbursement.
- Market Penetration: Increasing adoption could stabilize or slightly decrease per-dose pricing through volume discounts.
- Competitive Dynamics: Introduction of biosimilars or newer agents could apply downward pressure.
- Reimbursement Policies: Payer negotiations and value-based care models are significant.
Regulatory and Policy Impact
- No biosimilar approvals for Eptinezumab as of early 2023.
- Healthcare reforms and cost-control policies could influence drug pricing, with payers favoring lower-cost alternatives or biosimilar options in the future.
- FDA’s continuing surveillance on monoclonal antibodies and potential for label updates may impact market access.
Key Takeaways
- Eptinezumab entered a growing migraine prophylaxis market with significant unmet needs.
- Its intravenous route gives it a niche position, emphasizing rapid onset.
- The initial price of ~$3,200 per dose has remained relatively stable since launch, but market pressures forecast modest declines to ~$2,300 by 2028.
- Market leaders maintain pricing power through established brand presence and broad insurance coverage.
- Future outlook remains cautiously optimistic, with growth opportunities in specific patient populations and preventive therapy segments.
FAQs
1. How does Eptinezumab’s price compare to other CGRP inhibitors?
Eptinezumab’s initial price (~$3,200/dose) was lower than other subcutaneous CGRP inhibitors (~$6,900/month). Its pricing reflects different administration routes, with IV infusions incurring higher administration costs but lower drug prices.
2. What factors could accelerate price reductions for Eptinezumab?
Introduction of biosimilars, increased regional competition, and shifts toward value-based reimbursement models could prompt further price reductions. Market saturation and payer negotiations are critical.
3. Which patient groups are likely to drive Eptinezumab’s future sales?
Patients needing rapid, inpatient, or infusion-based prophylaxis, and those with poor response to SC CGRP agents, are primary candidates for Eptinezumab.
4. How does route of administration impact market adoption?
IV infusion requires clinic visits, affecting convenience and potentially limiting adoption compared to SC injections. However, it provides rapid relief which is advantageous in certain cases.
5. Are there significant barriers to market growth for Eptinezumab?
Yes. The need for infusion clinics, competition from established SC agents, and any emerging biosimilars or new therapies could impact growth trajectories.
References
- American Migraine Foundation. Migraine facts 2022.
- IQVIA. U.S. Prescription Data 2022.
- FDA. Eptinezumab (Vyepti) Approval Announcement. Feb 2020.
- EvaluatePharma. Market Forecasts 2023-2030.
- MedPageToday. CGRP inhibitor market analysis. 2022.
Note: Price projections are estimates based on current market trends and may change with evolving healthcare policies and market dynamics.
